“None of these scenarios are palatable.”
This assessment of #covid19 scenarios for the next months by SPI-M-O, one of the groups advising UK government, is really interesting. I wish public communication was this candid and consistently so.
It dismisses 3 scenarios as implausible without vaccine roll-out/therapeutics:
⁃eradication
⁃shielding high-risk groups while building up herd immunity
⁃“managed epidemic”, with little or no government interventions or behaviour change but little damage to economy or health
It also states clearly that “any economic evaluations of interventions should not be compared to a “COVID-free” world, as each of the scenarios have substantial economic implications.”
Then it walks through the consequences of the four scenarios in terms of health impacts, economic impacts, implications for holidays and vaccination. This is of course just a very rough analysis of implications, but this is how we should be talking about scenarios.
You’re probably all tired of me saying this, but European countries really need to think (and talk!) more about their #covid19 strategies.
This is public health 101.
People are generally more willing to go along with you if you tell them where you are going and why...
As I wrote earlier this month: Not making a decision probably leads to intermittent lockdowns as a default. As @AdamJKucharski told me then: “These circuit breakers are almost kicking the problem down the road.” sciencemag.org/news/2020/11/e…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Good vaccine news continues: @moderna_tx just announced its vaccine has shown 94,5% efficacy.
In the study of more than 30,000 participants, 95 #covid19 cases were observed (starting two weeks after second dose):
90 in placebo group
5 in vaccine group
@moderna_tx Like Pfizer/Biontech last week, this is an interim analysis of an ongoing study and this is a press release not a peer-reviewed article.
But this is one more indication that the first generation of #covid19 vaccines will work and work better than most had hoped for.
@moderna_tx Particularly interesting that Moderna also looked at severe cases of #covid19:
For this interim analysis there were 11 severe cases, all of them in the placebo group.
This does not mean that the vaccine prevents severe cases, but at least it is consistent with that.
Was so busy the last few days that I did not even have a chance to look at @WHO’s sitrep on #covid19 until today. As you can imagine it does not make for pleasant reading. But here goes:
@WHO Last week @WHO reported almost 3,7 million new cases of #covid19.
That’s a new record, of course.
It is more than 6 new cases every second!
WHO also reported 54,835 deaths from #covid19.
That’s roughly one person dying every 11 seconds.
@WHO Look at this graph:
We are climbing a mountain of death.
If things go well and effective vaccines really are rolled out in a few months to protect at-risk groups (maybe even curb spread of the virus), all these preventable deaths will seem even more senseless and cruel.
Yesterday, I pretended to be a normal infectious disease reporter for a day and wrote about an interesting new preprint: the first report of leprosy in wild chimpanzees.
Quick thread on why this is important before I get back to covering #covid19
Leprosy is a facinating disease: It is ancient and everyone has an image of it (hence the terrible stigma), but at the same time we know shockingly little about it, like when and where it emerged or how exactly it spreads.
One thing people were sure of: Leprosy afflicts only humans. That has turned out to not be quite true, however. Researchers have found leprosy in squirrels in UK and in armadillos in the Americas. In both cases it’s the same genotype (3I) that apparently came from humans.
This is important news too: Eli Lilly‘s monoclonal antibody bamlanivimab (that‘s the treatment Chris Christie received) has received an emergency use authorization in the US. Crucially this is not for hospitalized patients but for „mild-to-moderate #covid19“.
The data here is still thin. Decision is based on interim results from a phase 2 trial in which three different doses were tested against placebo. In all three bamlanivimab groups hospitalizations and ER visits were less likely than in placebo group.
And the cavets are important: This is an expensive drug given IV and giving it early in the disease course means giving it to a lot of people only some of whom really need it. Producing the drug would also be a bottleneck.
This is big news: Pfizer says early phase 3 data of its #covid19 vaccine developed with German company BioNTech shows it to be about 90% effective in preventing disease with no serious safety concerns. Remember this is preliminary, but reason to be hopeful nytimes.com/2020/11/09/hea…
This is based on a review of data after 94 people in the trial developed #Covid19. Final analysis is planned for when there have been 164 #covid19 cases in participants in the trial.
As usual, the caveats are as important as the results: We don’t know if these numbers will hold up. We don’t know how long immunity will last. Billions of doses will take time to produce. etc. But we are in a better place today than we were yesterday.
Unsurprisingly, there is a sense of relief today across the political spectrum in Germany and I thought I’d give you a flavor of sentiments here:
“We want the West to play as a team again. Only as a team will we effectively assert our shared values worldwide and have the necessary clout.” Foreign Minister @HeikoMaas
“Joe Biden’s declaration as President-elect has sparked enormous relief, hope & joy in the US, in Germany & around the globe! ... Congrats America!” @peteraltmaier, Minister for Economic Affairs and Energy.